NEOG Quote, Financials, Valuation and Earnings

Organon & Co. has a net margin of -7.09% compared to Neogen Corp.'s net margin of -13.6%. Neogen Corp.'s return on equity of -25.93% beat Organon & Co.'s return on equity of 27.46%.

Neogen Corp. has a consensus price target of $11.67, signalling upside risk potential of 3.89%. On the other hand Organon & Co. has an analysts' consensus of $9.29 which suggests that it could grow by 27.38%. Given that Organon & Co. has higher upside potential than Neogen Corp., analysts believe Organon & Co. is more attractive than Neogen Corp..

Neogen Corp. has a beta of 1.980, which suggesting that the stock is 98.002% more volatile than S&P 500. In comparison Organon & Co. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Neogen Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Organon & Co. offers a yield of 1.1% to investors and pays a quarterly dividend of $0.02 per share. Neogen Corp. pays -- of its earnings as a dividend. Organon & Co. pays out 47.41% of its earnings as a dividend. Organon & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Neogen Corp. quarterly revenues are $224.7M, which are smaller than Organon & Co. quarterly revenues of $1.5B. Neogen Corp.'s net income of -$15.9M is higher than Organon & Co.'s net income of -$205M. Notably, Neogen Corp.'s price-to-earnings ratio is 2,124.15x while Organon & Co.'s PE ratio is 10.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neogen Corp. is 2.77x versus 0.31x for Organon & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Outlook Therapeutics, Inc. has a net margin of -7.09% compared to Neogen Corp.'s net margin of -1338.77%. Neogen Corp.'s return on equity of -25.93% beat Outlook Therapeutics, Inc.'s return on equity of --.

Neogen Corp. has a consensus price target of $11.67, signalling upside risk potential of 3.89%. On the other hand Outlook Therapeutics, Inc. has an analysts' consensus of $5.38 which suggests that it could grow by 1177.63%. Given that Outlook Therapeutics, Inc. has higher upside potential than Neogen Corp., analysts believe Outlook Therapeutics, Inc. is more attractive than Neogen Corp..

Neogen Corp. has a beta of 1.980, which suggesting that the stock is 98.002% more volatile than S&P 500. In comparison Outlook Therapeutics, Inc. has a beta of 0.102, suggesting its less volatile than the S&P 500 by 89.777%.

Neogen Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Outlook Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neogen Corp. pays -- of its earnings as a dividend. Outlook Therapeutics, Inc. pays out -- of its earnings as a dividend.

Neogen Corp. quarterly revenues are $224.7M, which are larger than Outlook Therapeutics, Inc. quarterly revenues of -$1.2M. Neogen Corp.'s net income of -$15.9M is higher than Outlook Therapeutics, Inc.'s net income of -$23.1M. Notably, Neogen Corp.'s price-to-earnings ratio is 2,124.15x while Outlook Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neogen Corp. is 2.77x versus 53.83x for Outlook Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Prestige Consumer Healthcare, Inc. has a net margin of -7.09% compared to Neogen Corp.'s net margin of 16.48%. Neogen Corp.'s return on equity of -25.93% beat Prestige Consumer Healthcare, Inc.'s return on equity of 10.21%.

Neogen Corp. has a consensus price target of $11.67, signalling upside risk potential of 3.89%. On the other hand Prestige Consumer Healthcare, Inc. has an analysts' consensus of $77.83 which suggests that it could grow by 12.31%. Given that Prestige Consumer Healthcare, Inc. has higher upside potential than Neogen Corp., analysts believe Prestige Consumer Healthcare, Inc. is more attractive than Neogen Corp..

Neogen Corp. has a beta of 1.980, which suggesting that the stock is 98.002% more volatile than S&P 500. In comparison Prestige Consumer Healthcare, Inc. has a beta of 0.425, suggesting its less volatile than the S&P 500 by 57.452%.

Neogen Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Prestige Consumer Healthcare, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neogen Corp. pays -- of its earnings as a dividend. Prestige Consumer Healthcare, Inc. pays out -- of its earnings as a dividend.

Neogen Corp. quarterly revenues are $224.7M, which are smaller than Prestige Consumer Healthcare, Inc. quarterly revenues of $283.4M. Neogen Corp.'s net income of -$15.9M is lower than Prestige Consumer Healthcare, Inc.'s net income of $46.7M. Notably, Neogen Corp.'s price-to-earnings ratio is 2,124.15x while Prestige Consumer Healthcare, Inc.'s PE ratio is 18.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neogen Corp. is 2.77x versus 3.10x for Prestige Consumer Healthcare, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Teleflex, Inc. has a net margin of -7.09% compared to Neogen Corp.'s net margin of -0.62%. Neogen Corp.'s return on equity of -25.93% beat Teleflex, Inc.'s return on equity of -4.98%.

Neogen Corp. has a consensus price target of $11.67, signalling upside risk potential of 3.89%. On the other hand Teleflex, Inc. has an analysts' consensus of $135.50 which suggests that it could grow by 11.01%. Given that Teleflex, Inc. has higher upside potential than Neogen Corp., analysts believe Teleflex, Inc. is more attractive than Neogen Corp..

Neogen Corp. has a beta of 1.980, which suggesting that the stock is 98.002% more volatile than S&P 500. In comparison Teleflex, Inc. has a beta of 0.917, suggesting its less volatile than the S&P 500 by 8.269%.

Neogen Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Teleflex, Inc. offers a yield of 1.11% to investors and pays a quarterly dividend of $0.34 per share. Neogen Corp. pays -- of its earnings as a dividend. Teleflex, Inc. pays out 91.92% of its earnings as a dividend. Teleflex, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Neogen Corp. quarterly revenues are $224.7M, which are smaller than Teleflex, Inc. quarterly revenues of $569M. Neogen Corp.'s net income of -$15.9M is lower than Teleflex, Inc.'s net income of -$3.6M. Notably, Neogen Corp.'s price-to-earnings ratio is 2,124.15x while Teleflex, Inc.'s PE ratio is 25.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neogen Corp. is 2.77x versus 1.84x for Teleflex, Inc.. Usually stocks with elevated PS ratios are considered overvalued.